HOME >> BIOLOGY >> NEWS
Sitagliptin, a new investigational treatment for type 2 diabetes, may offer new hope for patients

There are currently more than 194 million people with diabetes worldwide and this figure could exceed 333 million by 2025 if untreated. [2] Current treatments for type 2 diabetes are often limited by their side effect profile, route of administration or difficulties in sustaining glucose control. [3] As a result, there is a need for better tolerated treatments that do not cause weight gain and produce less risk of hypoglycaemia for patients with type 2 diabetes. The results of the two Phase II studies indicate that sitagliptin, an investigational diabetes drug, appears to control blood sugar with a low incidence of hypoglycaemia and with a neutral effect on body weight.

In the Phase II studies of more than 1,000 patients, ''sitagliptin'', Merck Sharp & Dohme's investigational medicine from a new class of diabetes treatments called dipeptidyl peptidase 4 (DPP-4) inhibitors, improved glycaemic control in patients with type 2 diabetes and exhibited a safety and tolerability profile similar to placebo. In addition, patients taking sitagliptin experienced no significant weight gain and a low risk of hypoglycaemia.

"Results from the studies conducted to date are very promising," said Peter Stein, Senior Director in Clinical Research, Metabolism, Merck Research Laboratories, Rahway, NJ, USA. "The need for well tolerated therapies which achieve better glycaemic control than current therapies is well known and we are confident that these short-term clinical studies demonstrate proof of concept for sitagliptin, offering a new hope for type 2 diabetes patients. Ongoing Phase III trials should provide greater insight into the efficacy and tolerability profile of sitagliptin over a longer period of time".

Study 1: Effect of sitagliptin oral tablets on glycaemic control
Results from a 12-week, double-blind, placebo-controlled, parallel group study in patients with type 2 diabetes showed that sitagliptin oral tablets significantly r
'"/>

Contact: Catherine Pannell
cpannell@hillandknowlton.com
44-207-413-3059
Merck & Co., Inc.
14-Sep-2005


Page: 1 2 3

Related biology news :

1. FUZEON with investigational HIV drug results in remarkable number of patients achieving undetectable
2. Providence health system shows investigational osteoporosis therapy increases bone mineral density
3. Amgen investigational therapy, AMG 162, increased bone mineral density with twice yearly injection
4. New system of wastewater treatment could reduce the size of treatment plants by half
5. UCF research links proteins, stem cells and potential Alzheimers treatment
6. Geisinger scientist seeks cure for Lou Gehrigs disease, creating device to find treatment
7. System to analyze beating heart stem cells could lead to heart attack treatments
8. Gene expression pattern could lead to improved treatment of pediatric septic shock
9. Molecular detectors may refine cancer treatment
10. First genome-wide study of infectious disease opens new avenues for HIV treatment, vaccines
11. A new method of adult stem cell growth efficacious in treatment of disorders of the cornea

Post Your Comments:
(Date:11/4/2014)... of Utah engineers developed the first room-temperature fuel cell ... without needing to ignite the fuel. These new fuel ... power and sensors. , A study of the new ... journal ACS Catalysis . , Fuel cells convert ... fuel and an oxygen-rich source such as air. If ...
(Date:11/4/2014)... University School of Medicine announced today that it ... funded by the Bill & Melinda Gates Foundation. ... Gynecology and Reproductive Sciences; and Vice Chair of ... of Medicine will pursue an innovative global health ... to Assess Fetal Neurodevelopment.", Grand Challenges Explorations (GCE) ...
(Date:11/4/2014)... A newly published research study examining only marketing ... of fast food restaurants has found that the ... disproportionately exposed to such marketing tactics. , Authored ... her colleagues, the study is the first to ... interior and exterior of fast food restaurants and ...
Breaking Biology News(10 mins):Jet-fueled electricity at room temperature 2Temple University School of Medicine receives Grand Challenges Explorations grant 2Fast food marketing for children disproportionately affects certain communities 2Fast food marketing for children disproportionately affects certain communities 3
(Date:11/22/2014)... Quebec , November 21, 2014 ... wechselt als Chief Commercial Officer zu KLOX ... SVP der Unternehmensentwicklung und Chief Financial Officer bestellt    ... Europa mit der Vermarktung seines jüngst zugelassenen Behandlungssystems zur ... Inc. ("KLOX" bzw. das "Unternehmen") ist sehr erfreut, die ...
(Date:11/21/2014)... --  TRU-D SmartUVC LLC and its UK partners, Rapid ... robot, TRU-D SmartUVC, at FIS 2014 in Harrogate, ... at Stand 23. The conference, hosted by Federation ... largest infection-related event of its kind and brings together ... leading events of its type throughout the world. This annual ...
(Date:11/21/2014)... November 20, 2014 Offering a complete ... Sartorius Entris Balance promotion . The Sartorius Entris Balance ... durable, high accuracy, and easy-to-maintain balance entry level balance. ... It was designed to help customer’s bridge the gap ... balance that is very durable. Sartorius is the second ...
(Date:11/21/2014)... Alto, Calif. (PRWEB) November 20, 2014 ... a nonprofit, public policy research organization representing leading ... pharmaceutical firms, and PwC US today ... states in life sciences industry growth. The trend ... 2013. The 2015 California Biomedical Industry Report ...
Breaking Biology Technology:KLOX Technologies meldet Neubesetzung von Führungspositionen 2KLOX Technologies meldet Neubesetzung von Führungspositionen 3KLOX Technologies meldet Neubesetzung von Führungspositionen 4KLOX Technologies meldet Neubesetzung von Führungspositionen 5TRU-D SmartUVC to Showcase Superbug-Killing Robot at FIS 2014 2TRU-D SmartUVC to Showcase Superbug-Killing Robot at FIS 2014 3Pipette.com Announces an Extension on the Sartorius Entris Balance Promotion to the End of 2014 2California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 2California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 3California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 4
Cached News: